Acute kidney injury following percutaneous mechanical thrombectomy of subclavian artery stent graft thrombosis: a case report.

CVIR Endovasc

Department of Diagnostic and Interventional Radiology, University Hospital Merkur, Zajceva ul.19, 10000, Zagreb, Croatia.

Published: June 2020

AI Article Synopsis

  • A 66-year-old woman with a subclavian artery aneurysm experienced hand ischemia, leading to surgery with a stent graft, which later thrombosed.
  • After a procedure using AngioJet percutaneous mechanical thrombectomy (PMT) to clear the graft blockage, she developed acute kidney injury requiring dialysis.
  • This case highlights the potential risk of acute kidney injury following PMT, emphasizing the need for increased awareness and monitoring to minimize complications.

Article Abstract

Background: Percutaneous mechanical thrombectomy (PMT) is a well-established technique for treatment of acute arterial and venous thrombosis which inevitably leads to intravascular erythrocyte hemolysis, resulting in hemoglobinuria.

Case Presentation: We present a case of 66-year-old Caucasian female with subclavian artery aneurysm causing distal embolization and hand ischemia. The aneurysm was treated with stent graft, but with a subsequent graft thrombosis 3 months later. After graft recanalisation, AngioJet PMT was performed which resulted in dialysis-requiring acute kidney injury.

Conslusion: Only several cases of acute kidney injury following AngioJet PMT have been published in literature. To our knowledge, this is the first reported case of dialysis-requiring AKI after PMT for peripheral arterial thrombosis. Until there is sufficient evidence and recommendation on preventing AKI in this setting, we believe that by being aware of the risk and by monitoring of patient, one might minimize the damage in case it occurs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261712PMC
http://dx.doi.org/10.1186/s42155-020-00119-0DOI Listing

Publication Analysis

Top Keywords

acute kidney
12
kidney injury
8
percutaneous mechanical
8
mechanical thrombectomy
8
subclavian artery
8
stent graft
8
graft thrombosis
8
angiojet pmt
8
acute
4
injury percutaneous
4

Similar Publications

Cardiovascular-kidney-metabolic (CKM) syndrome is the association between obesity, diabetes, CKD (chronic kidney disease), and cardiovascular disease. GDF-15 mainly acts through the GFRAL (Glial cell line-derived neurotrophic factor Family Receptor Alpha-Like) receptor. GDF-15 and GDFRAL complex act mainly through RET co-receptors, further activating Ras and phosphatidylinositol-3-kinase (PI3K)/Akt pathways through downstream signaling.

View Article and Find Full Text PDF

Aim: SGLT2 inhibitors may be underused in older adults with type 2 diabetes due to concerns about safety and tolerability. This pooled analysis of the CANVAS Program and CREDENCE trial examined the efficacy and safety of canagliflozin according to age.

Methods: Pooled individual participant data from the CANVAS Program (n = 10 142) and CREDENCE trial (n = 4401) were analysed by baseline age (<65 years, 65 to <75 years, and ≥75 years).

View Article and Find Full Text PDF

Background: Severe intensive care unit-acquired hypernatraemia (ICU-AH) is a serious complication of critical illness. However, there is no detailed information on how this condition develops.

Objectives: The objective of this study was to study the prevalence, risk factors, trajectory, management, and outcome of severe ICU-AH (≥155 mmol·L).

View Article and Find Full Text PDF

Objective: Frusemide is a common diuretic administered to critically ill children intravenously, by either continuous infusion (CI) or intermittent bolus (IB). We aim to describe the characteristics of children who receive intravenous frusemide, patterns of use, and incidence of acute kidney injury (AKI), and to investigate factors associated with commencing CI.

Design: Retrospective observational study.

View Article and Find Full Text PDF

Objective: There is uncertainty about whether early infusion of intravenous amino acids confers clinical benefits in critically ill patients. In this study, we aimed to test the hypothesis that intravenous amino acids could improve 90-day mortality in critically ill patients with normal kidney function.

Design: This is a multicentre, open-label, randomised, parallel-controlled trial.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!